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Abstract
Background: Despite early diagnosis and treatment, Classical Galactosemia (CG) patients frequently develop long-term
complications, such as cognitive impairment. Available literature primarily reports on general intellectual abilities and
shows a substantially lower Full Scale Intelligence Quotient (FSIQ) in CG patients than in the general population. Both
problems in social functioning as well as internalizing problems are often reported in CG patients. The combination of
intelligence, cognitive functioning, behavior and social functioning has not been studied systematically in CG patients.
Methods: To determine if CG patients demonstrate a specific neuropsychological and psychosocial profile, we
investigated intelligence, functioning on multiple cognitive domains, behavior and social functioning with a
comprehensive neuropsychological test battery and questionnaires (self- and proxy-reported).
Results: The data of 48 patients, aged 4–47 years are reported. FSIQ ranged from 45 to 103 (mean 77 ± 14). A negative
correlation between age and FSIQ was demonstrated (p = 0.037) which resulted directly from the inclusion of four
young ‘milder’ patients detected by newborn screening (NBS) with an expected better clinical outcome. Compared to
normative data, patients had significantly lower but highly variable scores on all cognitive domains, especially on tests
requiring mental speed. In the context of the FSIQ, 43% of the cognitive test results exceeded IQ based expectations.
Overall, the patients’ scores on social functioning were in the normal range but internalizing problems were frequently
reported. In our cohort, an early initiation of dietary treatment due to NBS or family screening did not result in a more
favorable neuropsychological outcome.
Conclusions: In this study, we demonstrated that as a cohort, CG patients have a below average intelligence and
impaired cognitive functioning without a distinctive neuropsychological profile. The effect of age on neurocognitive
functioning should be assessed in longitudinal studies. Social functioning was not impaired, but patients may be at risk
for internalizing problems. Considering the large variability in cognitive, behavioral and social functioning and the
finding that cognitive outcomes may exceed IQ based expectations, an individual evaluation and follow-up is
warranted in all CG patients to ensure timely support if needed.
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Background
Classical Galactosemia (CG, OMIM 230400) is an auto-
somal recessive inborn error of galactose metabolism,
caused by a deficiency of the enzyme galactose-1-
phosphate uridylyltransferase (GALT, EC 2.7.7.12). The in-
gestion of galactose from breastmilk or infant formula in
the first weeks of life causes critical illness in affected neo-
nates. A lifelong galactose restricted diet is the only avail-
able treatment which is lifesaving in the newborn period
but does not prevent long-term complications such as cog-
nitive impairment, speech- and language deficits and move-
ment disorders [1–3]. A published systematic review and
meta-analysis demonstrated a substantially lower Full Scale
Intelligence Quotient (FSIQ) in CG patients compared to
the general population with large individual differences and
a FSIQ ranging from fully normal to severely impaired [4].
The cognitive outcome of CG patients reported in the lit-
erature is mainly based on intelligence tests that lead to IQ.
However, IQ is principally a dimension of individual differ-
ences in overall cognitive functioning called ‘general
intelligence’. It is the ultimate resultant of underlying more
specific abilities. These abilities are referred to as cognitive
functioning and encompass domains such as information
processing speed, attention, memory, visuospatial function-
ing and executive functioning. Previous studies reporting
on cognitive functioning in CG patients demonstrated
below average to low functioning on several cognitive
domains [5–9]. However, the outcomes on the cognitive
domains differed between studies and results must be inter-
preted with care because studies mostly addressed only one
cognitive domain, used one single test per cognitive domain
and/or included small cohorts. A recently published
systemic review demonstrated large differences between pa-
tients, but also suggested that specific cognitive impair-
ments may cause the lower level of intellectual functioning
observed in CG patients [10]. In order to investigate this
properly, a comprehensive neuropsychological assessment
addressing multiple cognitive domains with multiple tests
per domain should be performed.
Besides the cognitive difficulties, problems in social
functioning such as difficulties in making friends and
maintaining a stable relationship, as well as internalizing
behavior problems are often reported in CG patients and
affect quality of life [2, 9, 11–13]. It has been suggested
that CG patients exhibit autistic traits, however this has
not been studied systematically and should be investigated
in combination with social and behavioral functioning.
In order to provide patients with optimal support, more
insight into the neurocognitive, social and behavioral
functioning of CG patients is warranted. The aim of this
study was to investigate the neuropsychological function-
ing of CG patients by assessing the combination of general
intelligence, cognitive functioning on multiple domains,
social functioning and behavior and in a well-documented
cohort of pediatric, adolescent and adult patients with CG.
The effect of an early initiation of dietary treatment on
neuropsychological functioning will be evaluated as well.
Results
Of 67 CG patients visiting our multidisciplinary galacto-
semia expertise outpatient clinic and 6 CG patients treated
in other metabolic centers, 54 patients received a neuro-
psychological assessment. Six patients were excluded be-
cause patients did not consent with the use of their
clinical data for research purposes (n = 3), had a second
diagnosis influencing intellectual outcome (n = 1), the ad-
ministered tests were not part of our standardized assess-
ment (n = 1) and only a partly neuropsychological
assessment was available due to visual impairment (n = 1).
Demographics
In total, data of 48 patients are reported and demo-
graphics are presented in Table 1. The GALT erythro-
cyte activity was unknown in six patients with classical
phenotypes. Our cohort includes four variant patients
detected since the implementation of CG in the Dutch
newborn screening (NBS) program in 2007 with residual
erythrocyte GALT activity up 10% and possibly a better
clinical outcome [14]. Two patients are homozygous for
the p.Ser135Leu mutation with GALT deficiency in
erythrocytes but residual GALT enzyme activity in other
tissues which may improve clinical outcome [15]. The
two homozygous p.Ser135Leu patients in our cohort
were diagnosed late, at the age of 7 months and 10 years
respectively. In the pre-NBS group (n = 30) (diagnosis
based on clinical symptoms), with the exception of the
late diagnosed p.Ser135Leu patients, the diet was started
at a median age of 10 days [6, 39]. In the early treated
group (n = 18) (diagnosis by NBS or family screening),
the diet was started at a median age of 5.5 days (0-8).
Educational attainment
A total of 15 out of 48 patients (31%) attended or attend
to date special schools for primary education compared
to 4.5% in the general population [16] (Table 1). Of the
patients aged 12 years and older who completed primary
education, 9/32 (28%) attend or attended special schools
for secondary education compared to 3.0% in the general
population [16]. In the Netherlands, one of the eligibility
criteria for special education (smaller classes and tailored
education) is a FSIQ below 80.
Of the patients who completed their education, 6/15
completed education at a low educational level (of which
five completed special education), 8/15 completed educa-
tion at the secondary vocational level and 1/15 completed
education at a high educational level, which is lower when
compared to the general population (Table 1).
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General intelligence
The FSIQ ranged from 45 to 103, with a mean of 77
(Table 1). The FSIQ did not significantly differ between
males and females, nor between children and adults. Age
was significantly correlated with FSIQ (F (1, 46)=4.62, β-
0.42 (95%CI -0.82 – -0.03), p = .037).
The results of the VIQ, PIQ and FSIQ of the Wechsler
Scales of Intelligence are listed in Table 1. In 11 out of 48
patients, there was a significant difference of 15 or more
points between the PIQ and VIQ. In seven patients (five
adults and two children), this was in favor of the VIQ and
the gap between VIQ and PIQ ranged from 15 to 24 IQ
points. In four patients (all children), this was in favor of
the PIQ and the gap between PIQ and VIQ ranged from
15 to 30 IQ points.
FSIQ and educational attainment
In 15 adult patients, the highest level of completed edu-
cation was reported and in 5/15 (33%) this was special
education, while 13/15 (85%) had a FSIQ below 80. Of
Table 1 Patient Demographics
Variable All CG patients
Gender, n (%) Female: 28 (58)
Male: 20 (42)
Age (years) Median 16 (4–47)
GALT erythrocyte activity (%), n (%)
- < 3.3
- 3.3–8.7
- Unknown
36 (75)
6 (12.5)
6 (12.5)
Diagnosis based on (n):
- Clinical symptoms (pre-NBS)
- NBS
- FS
30
12
6
General Intelligence (n = 48)
FSIQ
VIQ
PIQ
Mean 77 (95% CI 72–80), SD 14
Mean 82 (95% CI 77–85), SD 15
Mean 78 (95% CI 73–81), SD 15
FSIQ, n (%)
- FSIQ < 70
- FSIQ ≥ 70–85
- FSIQ > 85–100
- FSIQ > 100
12 (25) (group 1)
20 (42) (group 2)
15 (31) (group 3)
1 (2) (group 3)
Wechsler scales (n) FSIQ VIQ PIQ
- WPPSI-IIINL (7)
- WISC-IIINL (19)
- WAIS-IVNL (22)
Mean 84, SD 11
Mean 79, SD 16
Mean 74, SD 13
Mean 84, SD 17
Mean 82, SD 16
Mean 81, SD 14
Mean 94, SD 6
Mean 76, SD 15
Mean 74, SD 13
Educational level, n (%)
- Elementary school (n = 48)
- Normal education
- Special education
- Unknown
25 (52)
15 (31)
8 (17)
- Secondary school (n = 32)
- Normal education
- Special education
- Unknown
- Not applicable (age < 12y)
16 (50)
9 (28)
7 (22)
16 (33)
- Educational attainment patientsa n = 17 Educational attainment Dutch population b
1. Low educational level
2. Secondary educational level
3. High educational level
Unknown
35%
47%
6%
12%
1.Low educational level
2. Secondary educational level
3. High educational level
Unknown
31.5%
38.5%
29%
1.5%
CG classical galactosemia, GALT galactose-1-phosphate uridyltransferase, NBS newborn screening, FS family screening, FSIQ full scale IQ, VIQ verbal IQ, PIQ
performal IQ, WPPSI Wechsler Preschool and Primary Scale of Intelligence, WISC Wechsler Intelligence Scale for Children, WAIS Wechsler Adult Intelligence Scale. a
Highest level of completed education, b Data from the Dutch National Bureau of Statistics
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the two patients with a FSIQ above 80, one patient com-
pleted secondary vocational education (FSIQ 81, 95%CI
77–87) and one patient completed higher professional
education (FSIQ 88, 95%CI 83–93).
FSIQ and the initiation of treatment
There was no significant difference in VIQ, PIQ and FSIQ
between patients in the pre-NBS group (n = 30) and early
treated patients (n = 18). The exclusion of the late diag-
nosed p.Ser135Leu patients (n = 2) and NBS detected vari-
ant patients (n = 4) did not change these results.
Cognitive functioning
The cognitive functioning test results are reported in
Table 2. The reported T-scores of patients were compared
to normative T-scores, based on a normative population
sample.
Learning & Memory
On the AVLT, patients demonstrated lower scores on Im-
mediate Recall, however the difference was not statistically
different after correction for multiple testing. On the other
two subtests, Delayed Recall and Delayed/Immediate Re-
call scores were comparable. On the Digit Span subtest,
which requires auditory verbal memory and verbal work-
ing memory, patients had significantly lower scores.
Visuospatial functioning
The visuospatial functioning of patients was assessed
with the GIT-2 spatial test and Block design. The signifi-
cantly lowers scores for patients indicate a lower (visuo)
spatial reasoning.
Executive functioning
Inhibition CG patients demonstrated significantly lower
scores on the Stroop Inhibition, indicating a poor (re-
sponse) inhibition. The comparable scores on the Stroop
Interference indicate that patients do not have an in-
creased sensitivity to interference.
Cognitive Flexibility Patients demonstrated lower
scores on both the TMT B/A and Letterfluency. This in-
dicates respectively that patients have an increased
Table 2 Cognitive Functioning Results
Domain N Results
patients
P-valuea N FSIQ 50–69
(Group 1)
N FSIQ 70–85
(Group 2)
N FSIQ > 85
(Group 3)
P-valueb
Learning & Memory
- AVLT Immediate Recall
- AVLT Delayed Recall
- AVLT Delayed / Immediate
- Digit span
19
19
19
35
46.0 (9–61)
46.0 (15–65)
52.0 (38–65)
43.0 (20–63)
0.029
0.545
0.445
< 0.0005c
4
4
4
8
40.0 (9–46)
49.5 (15–58)
55.5 (43–62)
30.00 (20–57)
11
11
11
15
45.00 (35–61)
46.00 (34–65)
52.00 (38–65)
43.00 (27–60)
4
4
4
12
49.50 (47–51)
50.00 (43–55)
52.00 (39–62)
48.50 (33–63)
0.121
0.956
0.803
0.017
Visuospatial functioning
GIT-2 spatial test
Block design
19
42
36.0 (23–50)
38.5 (20–53)
< 0.0005c
< 0.0005c
4
9
26.5 (23–40)
30.0 (20–40)
11
17
35.0 (28–40)
37.0 (27–50)
4
16
41.5 (40–50)
37.0 (33–53)
0.019
< 0.0005c
Executive functioning
Inhibition
- Stroop III (Inhibition)
- Stroop III/II (Interference)
25
25
45.0 (20–56)
49.0 (30–66)
0.003c
0.537
6
6
27.0 (20–49)
43.0 (30–60)
13
13
48.00 (22–56)
50.00 (31–66)
6
6
46.0 (35–53)
47.5 (40–63)
0.078
0.642
Cognitive flexibility
- WCST Total number of errors
- WCST Perseverative responses
- WCST Percent Cconceptual level responses
24
24
24
50.5 (27–67)
51.0 (30–81)
49.5 (27–64)
0.988
0.626
0.951
6
6
6
46.0 (27–50)
46.0 (33–52)
48.0 (27–51)
12
12
12
51.50 (37–67)
53.00 (30–81)
52.00 (39–64)
6
6
6
52.0 (39–64)
52.0 (35–73)
51.0 (37–62)
0.134
0.278
0.270
Responses
- TMT B/A
- Letter fluency
25
19
44.0 (27–57)
37.0 (27–67)
0.002c
0.001c
6
4
45.0 (27–50)
31.0 (28–38)
13
11
43.00 (27–57)
39.00 (31–67)
6
4
48.5 (40–57)
34.0 (27–56)
0.510
0.143
Mental Speed
- Stroop I (Color naming)
- Stroop II (Word reading)
- TMT A (Digit sequencing)
- TMT B (Digit-Letter-Switching)
- Symbol search
- Substitution
25
25
25
25
41
42
40.0 (25–61)
37.0 (20–56)
52.0 (20–67)
45.0 (20–58)
43.0 (20–67)
40.0 (23–57)
0.001c
< 0.0005c
0.352
0.003c
< 0.0005c
< 0.0005c
6
6
6
6
9
9
35.0 (25–43)
30.0 (20–40)
50.5 (20–59)
33.5 (20–47)
23.0 (20–50)
30.0 (23–47)
13
13
13
13
17
17
43.00 (35–61)
43.00 (20–56)
56.00 (43–67)
46.00 (20–58)
40.00 (27–67)
40.00 (30–57)
6
6
6
6
15
16
46.5 (33–55)
39.0 (33–56)
47.5 (33–67)
45.0 (33–56)
47.0 (40–60)
43.0 (33–53)
0.077
0.063
0.173
0.111
0.001c
0.006
Data reported in T-scores, median (ranges). a Patient data vs. normative data (T-score 50), b Comparison between FSIQ groups, c Significant after Bonferroni-Holm
correction. FSIQ full scale IQ, AVLT auditory verbal learning test, GIT-II groninger intelligentie test 2, Stroop stroop color word test, WCST wisconsin card sorting test,
TMT trail making test
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sensitivity to interference when it comes to cognitive
flexibility and less flexibility in generating words. The
comparable scores on all subtests of the WCST indicate
that on a group level patients seem to be able to switch
properly between strategies with a comparable amount
of errors and perseverative responses.
Mental speed
The scores on TMT part A, which assesses visual and
processing speed were comparable. The lower scores of
patients on Stroop I & II, TMT part B indicate that pa-
tients needed more time to complete the tasks. On
Symbol search and Substitution, which require process-
ing speed, focusing attention and visual perception, pa-
tients had significantly lower scores.
Cognitive functioning: NEPSY results
Considering the results of the NEPSY are expressed as
percentile rank scores, these results are reported separ-
ately and shown in Table 3. The NEPSY results of seven
children are quite comparable to the results of the older
patients reported above. On the NEPSY, approximately
half of the patients demonstrated scores below the refer-
ence range on inhibition tasks and predominantly scores
below the reference range on cognitive flexibility tasks.
The mental speed was also impaired considering all pa-
tients needed more time to complete the tasks, which may
indicate that inhibitory demands slow down cognitive pro-
cessing speed. Although patients needed more time, all
completed the NEPSY Naming and Switching tasks in the
reference range. The scores on the subdomain attention
indicate a poor selective and sustained attention.
Cognitive functioning and initiation of treatment
There was no significant difference in the cognitive
functioning results between patients in the pre-NBS
group and early treated patients. The exclusion of the
homozygous p.Ser135Leu patients (n = 2) did not change
these results.
Cognitive functioning in relation to general intelligence
The cognitive test results were compared between pa-
tients with a low FSIQ (50–69), an intermediate FSIQ
(70–85) and a normal FSIQ (> 85) (Table 2). On a group
level, no significant differences were found on cognitive
functioning between the FSIQ groups except for Symbol
search (domain mental speed) and Block design (domain
visuospatial functioning).
To evaluate if patients performed as expected based on
their intellectual abilities, cognitive functioning was also
individually evaluated in the context of the FSIQ. The re-
sults of the cognitive tests of adult and pediatric patients
are shown separately (Tables 4 and 5). Of the adult pa-
tients, 4/19 had one and 1/19 had two worse than ex-
pected test scores. All patients had at least one better than
expected test score. Of the pediatric patients, 4/17 patients
had a worse than expected test score on at least one and
at most three tests. A majority of the patients (12/17) had
at least one better than expected test result.
In total, 43% of the cognitive test results were better
than expected when evaluated in the context of the FSIQ.
BRIEF (behavior rating inventory of executive function)
questionnaire
Six parents completed the BRIEF-P questionnaire (data
not shown). On the Behavioral Regulation Index (BRI),
Table 3 NEPSY-II Results
NEPSY-II N Low percentile rank scoresa CG patients (n) Normal percentile rank scoresb CG patients (n)
Executive functioning
Inhibition
- Naming Total Errors
- Inhibition Total Errors
- Switching Total Errors
7
7
5
≤2 (1), 3–10 (1), 11–25 (1)
≤2 (1), 11–25 (2)
3–10 (1), 11–25 (2)
4
4
2
Cognitive flexibility
- Response Set, Total Correct 5 ≤2 (1), 3–10 (1), 11–25 (1) 2
Attention
- Auditory Attention, Total Correct 7 ≤2 (2), 3–10 (1), 11–25 (2) 2
Mental Speed
- Naming Total Completion Time
- Inhibition Total Completion Time
- Switching Total Completion Time
7
7
5
-
3–10 (2), 11–25 (5)
-
7
-
5
Data reported in percentile rank scores. CG classical galactosemia
alow percentile rank scores: ≤2: well below the reference level, 3-10: below the reference level, 11-25: borderline / just below the reference level,
bnormal percentile rank scores: 26-75: the reference level, >75: above the reference level
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Metacognition Index (MI) and the Total scale, one parent
reported T-scores in the subclinical range. Four adoles-
cents completed the BRIEF questionnaire. On the BRI, MI
and Total scale, one patient reported T-scores above 50,
but well below the clinical range of 65.
Eighteen adults completed the BRIEF-A questionnaire.
The median T-scores on the MI and Total Scale were
higher in patients compared to normative data, but these
differences were not significant after correction for mul-
tiple testing (p = .007). On the BRI, 7/18 patients (39%)
scored in the subclinical range and 1/18 (6%) reached
the clinical range. On the MI, 11/18 patients (61%)
scored in the subclinical range and 3/18 (17%) in the
clinical range. High scores on the MI were reported on
all subdomains (initiative, memory, planning and organ-
izing, task evaluation and tidiness). There was no signifi-
cant correlation between the FSIQ and the BRI, MI and
Total Scale on all used versions of the BRIEF (BRIEF-P,
BRIEF and BRIEF-A).
Behavioral functioning
CBCL (child behavior checklist) 6–18 years questionnaire
Parents reported scores in the subclinical and clinical
range of the Internalizing Problems scale only (Table 6).
On the subdomains of the Internalizing Problems scale,
‘withdrawn/ depressed’ and ‘somatic complaints’, parents
reported significantly higher scores compared to norma-
tive data. No significant correlation between any of the
CBCL outcome scales and FSIQ was found.
YSR (youth self report) questionnaire
A total of three adolescents completed the YSR ques-
tionnaire and did not report any problems on the In-
ternalizing, Externalizing and Total problems scales.
HADS (hospital anxiety and depression) questionnaire
Eighteen adults, four males (22%) and 14 females (78%)
with a median age of 25.5 years (18–47) completed the
HADS (Table 7). The results of patients were compared
to the norm data of 947 controls with a median age of
37.0 years (18–47) [17]. A higher percentage of patients
reported scores indicative for an anxiety disorder and
depression when compared to the reference group, but
the difference was not statistically significant. All pa-
tients reporting a score of 8 or higher have a FSIQ be-
tween 70 and 85.
Table 4 Individual Results, Adult Patients
ap.Ser135Leu homozygous patient. VIQ: Verbal IQ, PIQ: Performal IQ, FSIQ: Full Scale IQ, Stroop: Stroop Color Word Test, WCST: Wisconsin Card Sorting Test, PR:
Perseverative Responses, CLR: Conceptual Level Responses, TMT: Trail Making Test, AVLT: Auditory Verbal Learning Test, GIT-II: Groninger Intelligentie Test 2,
HADS: Hospital Anxiety and Depression Scale, BRIEF: Behavior Rating Inventory of Executive Function, SRS: Social Responsiveness Scale
X no test result, ■ test result worse than expected, test result better than expected, □ test result as expected
*X no result, - - T-score on total scale in clinical range, - T-score on total scale in subclinical range, □ T-score on total scale within normal range.
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Table 5 Individual Results, Pediatric Patients
ap.Ser135Leu homozygous patient, b Variant patient, VIQ: Verbal IQ, PIQ: Performal IQ, FSIQ: Full Scale IQ, NI: NEPSY Inhibition, Stroop: Stroop Color Word Test, RS:
Response Set, AA: Auditory Attention, WCST: Wisconsin Card Sorting Test, PR: Perseverative responses, CLR: Conceptual Level Responses. TMT: Trail Making Test,
AVLT: Auditory Verbal Learning Test, TCT: Total Completion Time, GIT-II: Groninger Intelligentie Test 2, CBCL 6–18y: Child Behavior Checklist 6–18 years, YSR: Youth
Self Report, BRIEF: Behavior Rating Inventory of Executive Function, SRS: Social Responsiveness Scale
X no test result, ■ test result worse than expected, ▪ test result better than expected, □ test result as expected
*X no result, - - T-score on total scale in clinical range, - T-score on total scale in subclinical range, □ T-score on total scale within normal range
Table 6 CBCL 6–18y Results: Internalizing and Externalizing Problems and Social Functioning
CBCL 6–18y, syndrome scale N Results patients Normative data T≥ 65 ≤ 68 (subclinical range) T > 68 (clinical range) P-value
CBCL 14
- Internalizing problems 58.0 (33–72) 50 0.157
• Anxious/depressed
• Withdrawn / depressed
• Somatic complaints
54.0 (50–74)
58.0 (50–68)
54.5 (50–64)
N = 2
N = 3
N = 0
N = 1
N = 0
N = 0
0.012
0.005*
0.003*
- Externalizing problems 37.5 (33–62) 0.018
• Rule-Breaking behavior
• Aggressive behavior
50.0 (50–60)
50.0 (50–62)
N = 0
N = 0
N = 0
N = 0
0.066
0.042
- WST 171 (150–201) 150 N = 2 N = 0 0.001*
• Withdrawn/ depressed
• Social problems
• Thought problems
58.0 (50–68)
56.5 (50–69)
51.0 (50–72)
50 N = 3
N = 1
N = 1
N = 0
N = 3
N = 1
0.005*
0.002*
0.007*
Data reported in T-scores, median (range). CBCL 6–18y: Child Behavior Checklist 6–18 years, WST: Withdrawn / depressed, Social problems & Thought problems.
* Significant after Bonferroni-Holm correction
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Social functioning
SRS (social responsiveness scale)
In total, 38 patients completed the SRS (Table 8). Seven
patients (18, 95%CI 11–36) had a T-score of ≥61 indicat-
ing a mild to moderate impaired social responsiveness.
One patient (2.6, 95%CI 0.5–13.5) had a T-score of ≥76
indicating a severe disruption of social interaction in
everyday life. Overall, the scores of patients were com-
parable to the normative data and individuals with ele-
vated scores were within the expected frequency (based
on a normal T-distribution the expected frequency of a
score ≥ 61 is 16% and of a score ≥ 76 is 0.6%). The differ-
ences in T-scores between children and adults and males
and females were not statistically significant. There was
no significant correlation between the FSIQ and SRS-2
and FSIQ and SRS-A.
CBCL 6–18 years, questionnaire
The T-scores on the subdomains 'withdrawn/ depressed',
's ocial problems' and 'thought problems', as well as its
sum (WST) were significantly higher in patients when
compared to normative data (Table 6). A minority of the
parents reported scores in the subclinical and clinical
range (on at least one and at most three domains).
Possible confounders
To evaluate the effect of possible confounders, additional
analyses were performed. Most pediatric patients under-
went limited cognitive testing due to their age. There-
fore, analyses were repeated without the data of patients
who underwent the Wechsler Scale of Intelligence and
just one additional cognitive test (i.e. the NEPSY), which
did not change the previous reported results.
The exclusion of patients with comorbidity (dyslexia
n = 2, ADHD n = 3, possible autism spectrum disorder
n = 2, neonatal meningitis n = 2, skull fracture n = 1) and
the exclusion of patients with scores indicative for an
anxiety disorder or depression, did not change the previ-
ously reported results.
Discussion
In this study, we aimed to investigate general intelligence,
cognitive functioning on multiple domains, behavioral and
social functioning in patients with CG. The results of this
study demonstrate that as a group, CG patients have a
below-average intelligence with a FSIQ of most patients
between 70 and 85. Compared to normative data, patients
demonstrated an overall impaired cognitive functioning,
especially on tests within the domains mental speed, ex-
ecutive- and visuospatial functioning.
In our cohort, mental speed and visuospatial function-
ing were the most frequently affected cognitive domains.
In previous studies, information processing speed (men-
tal speed) has also been reported to be impaired [7, 8],
but the finding that visuospatial functioning was affected
contradicts with previous research [7–9]. Until now, the
subdomains of the domain executive functioning were
not investigated separately. In our cohort, overall scores
indicated poor (response) inhibition and less (cognitive)
flexibility in generating words, but patients were able to
switch properly between tasks which requires cognitive
flexibility as well. Considering patients in our cohort
demonstrated less flexibility in generating words and
both receptive and expressive language impairments
have been reported in multiple case-studies, language
should be further investigated. On the domain learning
Table 7 HADS Results
HADS N Results patients Total score
≥ 8 < 11 (%)
Total score
≥ 11 (%)
N Results Reference
group
Total score
≥ 8 < 11 (%)
Total score
≥ 11 (%)
P- value
18 947
- Anxiety scale
- Depression scale
4.50 (1–16)
3.00 (0–13)
N = 1 (6%)
N = 0 (0%)
N = 3 (17%)
N = 1 (6%)
4.00 (0–17)
2.00 (1–19)
N = 109 (12%)
N = 82 (9%)
N = 71 (7%)
N = 38 (4%)
0.157
0.241
Data reported in median (range). HADS: Hospital Anxiety and Depression Scale
Table 8 SRS results
SRS N Results patients Normative data T≥ 61≤ 75 T > 75 P-value
SRS-2 (parent) 23
- Total 50.00 (40–85) 50 N = 3 N = 1 0.223
SRS-A (adult) 15
- Total 53.00 (39–75) 50 N = 4 N = 0 0.116
SRS (all) 38
- Total 52.50 (39–85) 50 N = 7 N = 1 0.073
Data reported in T-scores, median (range). SRS: Social Responsiveness Scale
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and memory, patients had more difficulty learning
words, but once learned the immediate and delayed re-
call were relatively spared in our cohort. Previous studies
indeed found no impairments on delayed and immediate
recall [7–9], even though a subset of patients did per-
form on an impaired level [10]. In order to correctly
interpreted the cognitive functioning results, it is im-
portant to evaluate them in the context of intellectual
abilities. Considering the included patients demonstrated
an overall below average intelligence and a correlation
between IQ and cognitive performance has been demon-
strated [18], the cognitive outcomes were compared be-
tween patients with a low FSIQ (50–69), an intermediate
FSIQ (70–85) and a normal FSIQ (> 85). Interestingly,
no significant differences in cognitive functioning be-
tween the three groups were found with the exception of
two tests (block design and symbol search) that directly
contribute to the FSIQ itself.
Considering the large differences in cognitive func-
tioning between patients within the same FSIQ group,
individual test results on cognitive functioning were
re-evaluated in the context of intellectual abilities,
which revealed that patients’ cognitive outcomes may
exceed IQ based expectations. This emphasizes the
general idea that the FSIQ is an ultimate resultant
that may not reflect underlying specific qualities and
vulnerabilities of the individual patient, and that a
more comprehensive neuropsychological evaluation
will provide a better insight in one’s strengths and
weaknesses. According to the literature, especially ex-
ecutive functioning is crucial for academic perform-
ance and has a predictive value for academic
achievement [19], which could also explain the higher
educational attainment in our patients than their
FSIQ would suggest.
Even though we investigated cognitive functioning on
multiple domains with multiple tests and evaluated scores
in context of the intellectual abilities, the large variability
in cognitive functioning remained and a clear profile could
not be distinguished. This variability complicates the
interpretation of results and makes it impossible to draw
an overall conclusion on cognitive functioning in CG. This
finding underlines the need for an individual assessment
in all patients. The large intra-individual variability in cog-
nitive functioning has been demonstrated in healthy adults
as well and the question remains whether found abnor-
malities indeed indicate the presence of brain dysfunction
[20]. Therefore results should be evaluated in the context
of daily functioning of the individual patient.
The VIQ and PIQ were evaluated as well. Overall, pa-
tients demonstrated a slightly higher VIQ than PIQ, which
is in line with previous studies [8, 21]. Considering the
broad standard deviations and confidence intervals and
small differences between VIQ and PIQ on a group level,
it cannot be concluded that verbal skills (as numerically
measured by VIQ) are better than non-verbal skills (PIQ).
In those patients with a significantly higher VIQ however,
this could potentially lead to an overestimation of the pa-
tients’ abilities due to relatively good verbal skills. This is a
relevant finding because in daily life this may put patients
at risk for excessive demands in relation to their more lim-
ited cognitive abilities.
On the BRIEF questionnaires, only a minority of
the already few parents reported executive functioning
problems in the subclinical and clinical range which
is in contrast to a vast majority of the adult patients.
This may be explained by the fact that the children
of these parents perform relatively well.
On the CBCL, all reported scores in the subclinical
and clinical range were reported on the internalizing
problems scale. Interestingly, on the YSR self-report,
adolescents reported no problems even though the
parents of two out of three patients reported scores
in the clinical range on the internalizing problems
scale. This is in line with a previous study which
demonstrated that parents reported more problems
than children, who might not experience or recognize
problems in their functioning [9]. On the subscales of
the CBCL indicative for social functioning (WST), CG
parents reported statistically significantly higher prob-
lem scores than population norms. However, only a
minority of parents reported scores in the subclinical
or clinical range. Scores on the SRS were comparable
to normative data and elevated scores indicating
problems in social functioning were only reported by
a minority of the patients. Importantly, our study did
not find increased levels of social irresponsiveness or
features suggestive of autism in CG. This is an im-
portant finding with regard to the observation that
CG patients would manifest autistic traits. Future re-
search is needed to understand poor social function-
ing in CG other than from deficits in the autism
spectrum. A recent study found impaired visual infor-
mation processing and facial emotion recognition in
CG patients, which might contribute to the difficulties
in social interactions observed in patients [22].
On the HADS, CG patients reported higher scores
on the anxiety and depression scales than the refer-
ence group. The fact that this difference was not sta-
tistically significant might be due to the small
numbers of patients included in this study. Since CG
patients may be at risk for anxiety and depression,
routine screening is warranted.
All but one patient reporting problems on the BRIEF and
all patients with elevated scores on the HADS had a FSIQ
between 70 and 85, suggesting that these patients may be at
risk to develop problems in everyday life. The fact that
these problems were not reported by patients with a FSIQ
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below 70 could indicate that they do not experience prob-
lems, are not aware of problems or simply have more diffi-
culty in expressing problems. Another explanation could be
that these patients are protected and guided more in every-
day life or that the questionnaires used are not suited for
patients with lower intellectual abilities.
Besides patients with classic phenotypes, our cohort
also included four NBS detected variant patients and
two patients with a homozygous p.Ser135Leu muta-
tion. The four variant patients received limited testing
due to their age. Even though these patients are still
young, they demonstrated a FSIQ above 85 and
scores on the cognitive tests in the normal range.
Follow-up of these patients is needed before it can be
concluded that these patients indeed have a better
neurocognitive outcome than patients with classical
phenotypes. Patients with a homozygous p.Ser135Leu
genotype are expected to have residual GALT enzyme
activity in different tissues, which may improve their
outcome. However, our two patients had a FSIQ of
71 and 61 and below average to low scores on several
cognitive tests. These two patients did not present
with critical illness in the neonatal period and were
diagnosed late which resulted in a prolonged exposure
to galactose which might explain this finding.
In our cohort, an early initiation of the diet because of
NBS or family screening did not result in a higher FSIQ
nor higher scores on the cognitive tests. Since most of
the early treated patients are young and therefore re-
ceived limited neuropsychological testing, follow-up is
warranted before definitive conclusions can be drawn.
At this time it is unclear whether neurocognitive func-
tioning declines with age as was suggested by cross-
sectional studies [8, 23, 24], but contradicted by longitu-
dinal studies [5, 21]. In our cross-sectional study, age
was negatively correlated with FSIQ. The exclusion of
the younger variant patients in our cohort with an ex-
pected better clinical outcome, resulted in a non-
significant correlation. Moreover, neurocognitive decline
should be assessed in longitudinal studies.
Limitations
Not all CG patients visiting our expertise outpatient
clinic underwent a neuropsychological assessment. Even
though the patient group who chose not to undergo a
neuropsychological assessment contains both patients
with normal cognitive functioning and patients with an
impaired cognitive functioning reported in their medical
charts, this may cause selection bias.
The data presented in this paper should be interpreted
with care because a small number of patients provides
statistical challenges. In adults, most T-scores on cogni-
tive functioning tests are corrected for educational at-
tainment, which might favor the results of the patients
since they perform on a lower education level compared
to the general population. However, significantly lower
scores were still shown in patients when compared to
the general population. Since patients have a substan-
tially lower FSIQ compared to the general population,
the individual results on cognitive functioning tests were
evaluated in the context of the FSIQ of patients. This is
indeed somewhat superficial, as the FSIQ arises from
subtests of cognitive abilities that correlate with one an-
other, and with the neuropsychological tests. Therefore,
this controlling for consistent variables gives rise to posi-
tive manifold and may overshadow relevant cognitive
impairments. Also, an interesting observation is that
general intelligence appears to account for a larger share
of cognitive variance in individuals exhibiting lower
intelligence (as measured by IQ or mental age) than in
individuals exhibiting higher intelligence [25].
In this study we did not intend to investigate the con-
structs of cognitive functioning. In order to assess cogni-
tive functioning on multiple domains, the categorization
of the domains as proposed by other studies was used
[10]. The division in domains is needed to properly in-
vestigate cognitive functioning, but it is important to be
aware that cognitive functioning tests may overlap be-
tween domains.
Longitudinal studies are needed to investigate apparent
age-related dynamic changes between the different scales
of intelligence as measured by the Wechsler scales. More-
over, re-assessment with latest iterations of the Wechsler
scales will provide practitioners and scientist with more
conceptual and practical insight into the developmental
processes and the complex concept of intelligence in CG.
Besides intelligence, cognitive functioning, behavior
and social functioning, there are other factors such as
adaptive skills, personal, family and environmental fac-
tors that influence functioning of individuals to a certain
extent and lay outside the scope of this article.
Adult patients completed the questionnaires during the
neuropsychological assessment, whereas most parents
completed the questionnaires at home. This resulted in a
limited number of returned questionnaires completed by
parents. The self-reported questionnaires might be hard
on patients with an intellecutal deficiency. Especially the
SRS was difficult for patients with a FSIQ below 70 and
therefore the results of these patients were not reported.
Strengths
In this study, we included all patients irrespective of
their expected neuropsychological outcome and ex-
cluded patients with a second (genetic) diagnosis, which
could influence neuropsychological functioning. There-
fore, this is not only a relatively large but also a repre-
sentative CG cohort.
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The assessment of cognitive functioning on specific do-
mains with the use of multiple tests per domain provides a
more reliable insight into the neuropsychological function-
ing of CG patients, than when only one test per domain is
administered. The results of pediatric and adult patients
were combined where possible. Since most pediatric pa-
tients received limited testing due to their age, analyses
were repeated after the exclusion of these patients. The ex-
clusion of these patients did not change the results and did
not provide a more distinctive neuropsychological profile.
Since comorbidity, such as ADHD, autism, neonatal
meningitis and dyslexia may cause executive functioning
impairment [26] and anxiety and depression might be
related to cognitive impairment and executive dysfunc-
tioning in particular [27], analyses were repeated after
the exclusion of these patients, however this did not
change the results.
Conclusions
The current study provides insights in general intelligence,
functioning on multiple cognitive domains, behavior and
social functioning of patients with CG. As a group, pa-
tients have a substantially lower IQ and impaired cognitive
functioning when compared to the general population and
may be at risk for internalizing problems. Importantly, in-
dividual differences are considerable and specific cognitive
abilities may exceed expectations that are based on the IQ.
Based on the findings of our study, an individual neuro-
psychological assessment including the evaluation of be-
havior and social functioning is advised in all CG patients.
In order to provide patients with timely and optimal sup-
port, the results of the neuropsychological assessment
should be evaluated in a broader context, which includes
adaptive functioning, the support system, the educational
level and the capacity of patients and should include
follow-up. This to ensure patients can reach their full po-
tential without being subjected to excessive cognitive and
emotional demands.
Methods
Patients and recruitment
All pediatric and adult patients with CG, visiting our
multidisciplinary galactosemia expertise outpatient clinic,
were offered a standardized neuropsychological assess-
ment as part of patient care according to the International
guideline for CG patients [28]. Adult patients (≥18 years)
or parents of patients (< 18 years) were asked to complete
the Social Responsiveness Scale (SRS). CG patients who
are treated in other metabolic centers but participated in
research in our outpatient clinic and recently received a
neuropsychological assessment, data were retrieved after
informed consent and incorporated if admissible.
Inclusion and exclusion criteria
All patients with erythrocyte GALT activity < 15% of the
reference mean and/or two known pathogenic variations in
the GALT gene were eligible for participation in this study.
All patients with a second genetic diagnosis influen-
cing clinical outcome were excluded. The results on cog-
nitive functioning of patients with a FSIQ below 50 were
excluded. The SRS of adult patients with an unknown
FSIQ or a FSIQ below 70 were excluded.
Neuropsychological measures
The comprehensive neuropsychological assessment is
summarized in Additional file 1: Table S8 and includes
standardized tests that cover:
– General intelligence
– Cognitive functioning on the domains: learning and
memory, visuospatial functioning, executive
functioning and mental speed.
– Questionnaires (self- and proxy reported) on
executive functioning, behavior and social
functioning
In children, Wechsler’s Verbal IQ (VIQ) and in adults
Wechsler’s Verbal Comprehension Index (hereafter VIQ) indi-
cates verbal functioning. In children, Wechsler’s Performance
IQ (PIQ) and in adults Wechsler’s Perceptual Reasoning Index
(hereafter PIQ) indicates non-verbal functioning.
Since it has been demonstrated that the subscales
Withdrawn / depressed, Social problems and Thought
problems (WST) of the Child Behavior Checklist (CBCL)
6–18y can be used to assess social functioning [29, 30],
these subscales and its sum were evaluated as well.
Data collection
The results of the neuropsychological assessment and
data on educational attainment were collected and
stored in an electronic clinical report form in Castor
Electronic Data Capture, a good clinical practice compliant
data management system [31].
Statistical analysis
SPSS version 25.0 (SPSS Inc. Chicago, Illinois, USA) was
used to perform all statistical analyses. Descriptive ana-
lyses included means and standard deviations if data was
normally distributed and median and ranges in case of a
non-normal distribution. General intelligence was stan-
dardized to an IQ-score (mean 100, SD15). All scores on
cognitive functioning tests and questionnaires were stan-
dardized to T-scores (mean 50, SD10), except for the
HADS (Hospital Anxiety and Depression Scale) which is
scored according to a Likert scale (0–3) resulting in a
total score and the Developmental NEuroPSYchological
Assessment (NEPSY) scores, which are expressed as
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percentile rank (pr) scores, ranging from well below the
reference level (pr < 2) to above the reference level (pr >
75). Depending on the cognitive tests used, the standard-
ized T-scores were corrected for age and/or gender and
in adults most cognitive tests were corrected for educa-
tional attainment as well. The T-scores of patients were
compared to normative data as reflection of the general
population (T-score 50) with the use of the non-
parametric sign test. A preliminary analysis showed a
large variability in the FSIQ of patients. The effect of the
FSIQ on cognitive functioning was evaluated by dividing
patients into three FSIQ groups; group 1: FSIQ 50–69,
group 2: FSIQ 70–85 and group 3: FSIQ > 85. Hereafter,
individual cognitive test results were re-evaluated in the
context of the FSIQ. More specifically, the FSIQ was
converted into a T-score and was compared to the T-
scores on the cognitive tests. In case a patient scored
-1SD (T-score ≤ 10) beneath their expected T-score, the
cognitive test score was considered ‘worse than expected’
and a score above +1SD (T-score ≥ 10) was defined as
‘better than expected’ based on the FSIQ. Differences be-
tween groups were tested with the Kruskal Wallis test or
Mann-Whitney U- test where appropriate. For the Hos-
pital Anxiety and Depression Scale (HADS), the results
of the patients were compared to the norm data of a ref-
erence group [17]. The Spearman’s rank coefficient test
was used to test for correlations and in case of a signifi-
cant correlation, linear regression was performed. To
evaluate the effect of possible confounders on our data,
additional analyses were performed after the exclusion
of patients with very limited data and patients with co-
morbidity potentially affecting cognitive functioning. To
evaluate the effect of an early initiation of the diet on
neurocognitive outcome, patients diagnosed before the
introduction of newborn screening (pre-NBS) with a
clinical presentation were compared to patients with an
early diagnosis based on NBS or family screening (be-
cause of an older sibling with CG). P-values below 0.05
were considered statistically significant. Multiple tests
regarding a single hypothesis were corrected with the
Bonferroni-Holm correction.
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